<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210708051822N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-02</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of probiotics in the therapy of Pediatrics  Burn</public_title>
      <acronym>پروبیوتیک در سوختگی</acronym>
      <scientific_title>Effect of probiotics in the therapy of Pediatrics thermal Burn: A prospective double- blind, controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57410</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: After hospitalization, patients will be divided in two group of case (probiotic) and control(placebo) by simple randomization, Blinding description: The packages of probiotic  and placebo will be designed in the same form.
Only principle investigator knows the content of packages . Patient and investigator or clinician are blind.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Thermal Burn in children.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Probiotic supply group that will receive oral package including 1- lactobacillus rhamnosus 2- lactobacillus rotteri 3- lactobacillus acidophilus 4-lactobacillusbulgaricus 5- lactobacillus casei 6-Bifidobacterium infantis 7-Bifidobacterium breve 8-Bifidobacterium bifidum 9-Bifidobacterium lactis 10- Streptococcus thermophilus with density of CFU 109 plus prebiotic of Fructooligosaccharides. This package is Gluten free and produced by Farabiotic Company . This oral powder will be used twice daily for 14 days by 50 cases of control group. Intervention 2: Control group: They will receive a package of placebo including  food material and in the same form of probiotic package. The oral placebo is produced by Farabiotic company and will be used by 50 cases of control group twice daily for 14 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There are no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossein Masoumi Asl</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 9, Frereshte  yekom Ave, Fereshteghak St, Marzdaran Blv, Tehran</address>
        <city>تهران</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1463774188</zip>
        <telephone>+98 21 4438 0119</telephone>
        <email>masoumiasl.h@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hossein Masoumi Asl</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, Fereshte yekom, fereshteghan st. , Marzdaran Blv, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1463774188</zip>
        <telephone>+98 21 4438 0119</telephone>
        <email>masoumiasl.h@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children between 1-15 years old
Burn with total body surface area 10-50%
Burn with deep area between 5-10%</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>15 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Children with chronic GI diseases
Children with chronic  diseases for example diabetes
Children with upper respiratory tract or inhalation injury
Children with hereditary and congenital immune system disorders
children with chemical and electrical burn</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T20-T32</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Burn and corrosion</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Probiotic supply group that will receive oral package including 1- lactobacillus rhamnosus 2- lactobacillus rotteri 3- lactobacillus acidophilus 4-lactobacillusbulgaricus 5- lactobacillus casei 6-Bifidobacterium infantis 7-Bifidobacterium breve 8-Bifidobacterium bifidum 9-Bifidobacterium lactis 10- Streptococcus thermophilus with density of CFU 109 plus prebiotic of Fructooligosaccharides. This package is Gluten free and produced by Farabiotic Company . This oral powder will be used twice daily for 14 days by 50 cases of control group.</i_keyword>
      <i_keyword>Control group: They will receive a package of placebo including  food material and in the same form of probiotic package. The oral placebo is produced by Farabiotic company and will be used by 50 cases of control group twice daily for 14 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The rate of infection  in thermal burn of children. Timepoint: Zero (admission day), 4, 7 and 14 day and until one year after hospitalization. Method of measurement: To calculate the number of positive culture reported by laboratory in thermal burn of children according to patients file.</prim_outcome>
      <prim_outcome>The length of hospital stay in thermal burn of children. Timepoint: Time of discharge or death. Method of measurement: To calculate the length of hospital stay on the time of discharge or death  according to patients file.</prim_outcome>
      <prim_outcome>The need to skin graft in thermal burn of children. Timepoint: From discharge until one year. Method of measurement: To calculate the number of skin graft from discharge until one year according to patients file.</prim_outcome>
      <prim_outcome>Mortality due to  thermal burn of children. Timepoint: From hospitalization until one year. Method of measurement: The mortality rate ( the proportion of death to number of hospitalized patients)  in thermal burn of children.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Length of hospital stay. Timepoint: Date of discharge and one year after burn. Method of measurement: Number of hospitalized days.</sec_outcome>
      <sec_outcome>The need to skin graft. Timepoint: From discharge until one year after burn. Method of measurement: The number of skin grafts.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-06-12</approval_date>
        <contact_name>Research Ethics Committees of Iran University of Medical Sciences</contact_name>
        <contact_address>Ethics Committees of Iran University of Medical Sciences, Central building of Iran University of Medical Sciences, next to Milad tower, Hemmat highway, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
